Categories: News

Osstem Implant Strengthens Position in India, Reinforcing the Global Reputation of ‘K-Implant’

SEOUL, South Korea, Aug. 28, 2025 /PRNewswire/ — India’s dental implant sector is undergoing a significant transformation. With rapid economic growth, rising middle-class income, and increasing life expectancy, patients are prioritizing quality and advanced technology over cost when seeking dental care. Osstem Implant, Korea’s leading dental implant manufacturer, is at the forefront of this transformation, emerging as a trusted partner for Indian dentists and patients alike.

- Advertisement -

Traditionally, the global dental implant industry was dominated by European manufacturers. In recent years, Korean companies have emerged as strong competitors, reshaping the competitive landscape. Osstem Implant now ranks third in global market share, exporting to over 100 countries and operating 37 subsidiaries across 32 nations. India is one of the fastest-growing markets and has become a key pillar of the company’s international expansion strategy.

- Advertisement -

Osstem Implant’s success in India is driven by a dual focus on innovation and education. The company offers five implant designs and four surface technologies, providing tailored solutions for diverse patient needs. Its implants deliver strong initial stability, reducing treatment time. They also maintain long-term reliability, enhancing patient satisfaction. At the same time, Osstem invests heavily in training local dentists. Its flagship “Master Course” was held over 100 times across India last year, with more than 1,300 dentists completing the program. These initiatives have strengthened the clinical skills of Indian practitioners and created a confident local network proficient in Osstem systems.

- Advertisement -

The company’s technological excellence is supported by strong scientific evidence. Research published in the international journal Materials highlighted the effectiveness of Osstem’s SA surface treatment in promoting osseointegration and bone density. Its best-selling product, TS III, has consistently demonstrated high clinical success rates across multiple studies. Indian dentists have echoed these findings, reporting faster recovery times and higher patient satisfaction compared with other products on the market.[1]

- Advertisement -

In 2024, Osstem Implant reported consolidated revenues of USD 930 million (approximately KRW 1.3 trillion), with nearly 70% generated from overseas markets. India, along with China and Russia, showed particularly strong growth. Analysts note that this success is driven not by low-cost strategies but by continuous R&D, product innovation, and professional education.

- Advertisement -

Dental implants play a crucial role in long-term patient well-being. By providing world-class implant solutions and strengthening collaboration with local practitioners, Osstem Implant is helping elevate dental care standards in India, while reinforcing the ‘K-Implant’ as a global symbol of quality and innovation.

- Advertisement -

Reference:

- Advertisement -

Photo – https://mma.prnewswire.com/media/2756872/Osstem_Implant_s_Quality_Certifications_Leading_Countries.jpg

- Advertisement -

View original content:https://www.prnewswire.com/in/news-releases/osstem-implant-strengthens-position-in-india-reinforcing-the-global-reputation-of-k-implant-302540720.html

- Advertisement -

Recent Posts

Singtel Receives Four Frost & Sullivan 2026 Recognitions for Leadership in Enterprise Connectivity, Cybersecurity, and Digital Transformation

The recognitions highlight Singtel's leadership in secure connectivity, network transformation, IoT innovation, and cybersecurity, delivering…

10 hours ago

4DMT Announces Positive 2-Year Data from PRISM Phase 2b Clinical Trial in a Broad Wet AMD Population

July 18, 2026 15:15 ET  | Source: 4D Molecular Therapeutics, Inc. After a single intravitreal…

11 hours ago

Immuneering Corporation Announces Grants of Inducement Awards

NEW YORK, July 17, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical…

11 hours ago

FDA Approves First Oral PCSK9 Inhibitor to Lower LDL Cholesterol in Adults with High Cholesterol

Silver Spring, MD, July 17, 2026 (GLOBE NEWSWIRE) -- The U.S. Food and Drug Administration approved Lipfendra…

11 hours ago

Vitalist Announces Notice of Meeting & Record Date

CALGARY, Alberta, July 17, 2026 (GLOBE NEWSWIRE) -- Vitalist Inc. (TSX-V: VITA.V; OTCQB: VTLSF) ("Vitalist",…

16 hours ago

SPIRIT BLOCKCHAIN CAPITAL ANNOUNCES RESULTS OF ANNUAL GENERAL MEETING AND BOARD CHANGES

July 17, 2026 17:00 ET  | Source: Spirit Blockchain Capital Inc. VANCOUVER, Canada, July 17,…

16 hours ago